Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 weekly schedule in HER2-positive advanced gastric cancer without measurable metastatic lesion (HERBIS-1B) (OGSG 1202)

Trial Profile

Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 weekly schedule in HER2-positive advanced gastric cancer without measurable metastatic lesion (HERBIS-1B) (OGSG 1202)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Trastuzumab
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-1B
  • Most Recent Events

    • 19 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2015 Planned End Date changed from 21 Feb 2019 to 31 May 2018 as reported by University Hospital Medical Information Network - Japan record.
    • 16 Nov 2014 Planned End Date changed from 21 Feb 2017 to 21 Feb 2019 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top